Intellia Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$10.99(as of Aug 15, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Intellia Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$10.99
Ticker SymbolNTLA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees403
CountyUSA
Market Cap$1,179.7M
EBIDTA-501.9M
10-Day Moving Average11.18
P/E Ratio-2.37
20-Day Moving Average11.98
Forward P/E Ratio0.00
50-Day Moving Average10.78
Earnings per Share-4.69
200-Day Moving Average10.72
Profit Margin-710.81%
RSI46.04
Shares Outstanding107.3M
ATR0.76
52-Week High24.16
Volume4,768,606
52-Week Low5.90
Most Recent Support Level10.65
Book Value715.3M
Most Recent Resistance Level11.51
P/B Ratio1.59
Upper Keltner13.69
P/S Ratio21.57
Lower Keltner10.27
Debt-to-Equity Ratio13.69
Next Earnings Date11/06/2025
Cash Surplus60.7M
Next Ex-Dividend DateUnknown

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics Inc In Our Stock Scanner

As of Aug 18, 2025
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Discounted Stocks with Earnings GrowthScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Long Legged DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.